Theravance Inc news

   Watch this stock
Showing stories 1 - 4 of about 4   

Articles published

THRX 9.08 +0.05 (0.55%)
price chart
GlaxoSmithKline boosts Theravance stake
Following approval Tuesday by Theravance stockholders, GSK's previously announced acquisition of 10 million shares of Theravance is now complete - meaning GSK owns 25.8 million shares of Theravance common stock. That's 26.7 percent of the total ...
Tracking Seth Klarman's Baupost Group Holdings: Q1 2012 Update
Theravance Inc (NASDAQ:THRX): THRX, approximately 10% of the US long portfolio position, was increased marginally this quarter.
Seth Klarman Betting Big On These 2 Stocks
Seth Klarman's Baupost Group is one of the largest hedge funds and regarded very highly in the world of "Graham-Dodd" value investors.
Biopharma raising $500K eyes competitive asthma/COPD drug market
Recent U.S. Food and Drug Administration approvals have included Merck's combination drug Dulera, Novartis/Genentech's Xolair and Novartis/Schering-Plough's Foradil, plus a new nondrug treatment called bronchial thermoplasty.